AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
QUEBEC CITY, April 15, 2009 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two posters on its PI3K inhibitor compound, AEZS-126, as well as a poster on its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, at the American Association for Cancer Research (AACR) Annual Meeting, to be held on April 18-22, 2009 at the Colorado Convention Center in Denver, Colorado.
AEZS-126 (Poster #3705) - Entitled, "AEZS-126, a new orally bioavailable PI3K inhibitor with antitumor effects", I. Seipelt, S. Baasner, M. Gerlach, M. Teifel, J. Fensterle, L. Blumenstein, G. Mueller and E. Guenther, the poster focuses on ADMET and safety profiling of the compound, as well as in vivo pharmacokinetic experiments and mouse xenograft antitumor studies. AEZS-126 (Poster #3706) - Entitled, "In vitro profiling of the potent and selective PI3K inhibitor, AEZS-126", I. Seipelt, M. Gerlach, L. Blumenstein, G. Mueller, M.Teifel, E. Polymeropoulos and E. Guenther, the poster outlines the key in vitro characteristics of this compound that led to its selection for in vivo development. Both posters will be presented on Tuesday, April 21, 2009, between 8 a.m. and 12 p.m. (MT), during the Experimental and Molecular Therapeutics 23 session in Hall B-F, Poster Section 35. AEZS-112 (Poster #5567) - Entitled, "Phase I dose-escalation, safety, and pharmacokinetic study of weekly oral AEZS-112, a small molecule anticancer agent in patients with advanced cancer and lymphoma", D. W. Northfelt, P. Griffin, H. Block, H. Sindermann, M. Teifel, D. Von Hoff, D. Mendelson, the poster outlines Phase 1 results for this orally-active tubulin and topoisomerase II inhibitor compound, in patients with advanced solid tumors and lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer. The poster will be presented on Wednesday, April 22, 2009, between 8 a.m. and 12 p.m. (MT) during the Experimental and Molecular Therapeutics 42 session in Hall B-F, Poster Section 37.
Copies of the abstracts that served for these posters are currently available and can be viewed on-line through the AACR 2009 Meeting website at: http://www.abstractsonline.com/viewer/?mkey=%7BD007B270%2DE8F6%2D492D%2D803B%2D7582CE7A0988%7D
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.
CONTACT: Investor Relations: Ginette Vallieres, Investor RelationsCoordinator, (418) 652-8525 ext. 265, ; MediaRelations: Paul Burroughs, Director of Communications, (418) 652-8525 ext.406, email@example.com firstname.lastname@example.org
Ticker Symbol: (Toronto:AEZ),(NASDAQ-NMS:AEZS)
Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: April 2009